13 Aug 2024 , 12:48 PM
Alembic Pharmaceuticals Limited today said it has got the final approval from the US Food and Drug Administration for Dabigatran Etexilate Capsules, 110 mg.
The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals, Inc., the company said.
Dabigatran Etexilate Capsules 110 mg are indicated for prophylaxis of deep vein thrombosis and pulmonary embolism following hip replacement surgery.
Alembic has a cumulative total of 211 ANDA approvals, including 183 final approvals and 28 tentative approvals, from the US FDA.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice